CoChat

Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study

Open access
Sheehan, Megan M, Reddy, Anita J, Rothberg, Michael B · 2021 · Clinical Infectious Diseases

Published version of a preprint

Cited by 132

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: Protection afforded from prior disease among patients with coronavirus disease 2019 (COVID-19) infection is unknown. If infection provides substantial long-lasting immunity, it may be appropriate to reconsider vaccination distribution. Methods: This retrospective cohort study of 1 health system included 150 325 patients tested for COVID-19 infection via polymerase chain reaction from 12 March 2020 to 30 August 2020. Testing performed up to 24 February 2021 in these patients was included. The main outcome was reinfection, defined as infection ≥90 days after initial testing. Secondary outcomes were symptomatic infection and protection of prior infection against reinfection. Results: Of 150 325 patients, 8845 (5.9%) tested positive and 141 480 (94.1%) tested negative before 30 August. A total of 1278 (14.4%) positive patients were retested after 90 days, and 62 had possible reinfection. Of those, 31 (50%) were symptomatic. Of those with initial negative testing, 5449 (3.9%) were subsequently positive and 3191 of those (58.5%) were symptomatic. Protection offered from prior infection was 81.8% (95% confidence interval [CI], 76.6–85.8) and against symptomatic infection was 84.5% (95% CI, 77.9–89.1). This protection increased over time. Conclusions: Prior infection in patients with COVID-19 was highly protective against reinfection and symptomatic disease. This protection increased over time, suggesting that viral shedding or ongoing immune response may persist beyond 90 days and may not represent true reinfection. As vaccine supply is limited, patients with known history of COVID-19 could delay early vaccination to allow for the most vulnerable to access the vaccine and slow transmission.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciab234

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 6

  1. Wu, 2020, Substantial underestimation of SARS-CoV-2 infection in the United States, Nat Commun, 11, 4507, 10.1038/s41467-020-18272-4 · DOI · Paper page
  2. Tillett, 2021, Genomic evidence for reinfection with SARS-CoV-2: a case study, Lancet Infect Dis, 21, 52, 10.1016/S1473-3099(20)30764-7 · DOI · Paper page
  3. Van Elslande, Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain, Clin Infect Dis
  4. Pilz, 2021, SARS-CoV-2 re-infection risk in Austria, Eur J Clin Invest, 51, e13520, 10.1111/eci.13520 · DOI · Paper page
  5. Vibholm, 2021, SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses, EBioMedicine, 64, 103230, 10.1016/j.ebiom.2021.103230 · DOI
  6. Harvey, 2021, Association of SARS-CoV-2 seropositive antibody test with risk of future infection, JAMA Intern Med, 10.1001/jamainternmed.2021.0366 · DOI · Paper page

Cited by

Metadata

Authors
Sheehan, M. M., Reddy, A. J., & Rothberg, M. B.
Venue
Clinical Infectious Diseases
Published
2021-03-15
Volume
73
Issue
10
Pages
1882-1886
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W3211430680
Cited by
132
References
9
FWCI
9.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.